title: Treatment of hepatocellular carcinoma and the exacerbation of liver function.
abstract: We performed interventional treatments on 50 patients with hepatocellular carcinoma (HCC) and analyzed the relationship between these treatments and the exacerbation of liver function after treatment. The different treatments included transcatheter arterial embolization (TAE), percutaneous ethanol injection therapy (PEIT), selective segmental sclerotherapy (SSS), combined TAE and PEIT, or transcatheter arterial chemo-injection (TAI). Thirteen patients showed an exacerbation of liver function after treatment. The laboratory data on admission, showed the lower levels of serum albumin and cholinesterase in this group. In comparison to patients who did not show any exacerbation of liver function, these 13 patients had undergone combined TAE and PEIT. An analysis of cases after TAE and PEIT treatment revealed that the time from TAE to PEIT was shorter in the exacerbation group than in the non-exacerbation group, however, there was no significant difference in the amount of injected ethanol between the two groups. It is assumed that the values of albumin and cholinesterase before treatment, or the period from TAE to PEIT are related to liver failure after treatment. Combining TAE and PEIT treatment may be effective for HCC, however, we should pay special attention to liver failure after treatment.
authors.affiliation: First Department of Internal Medicine, Mie University School of Medicine, Tsu 514-8507, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Okano
authors.forename: K
authors.initials: K
authors.lastname: Shiraki
authors.forename: H
authors.initials: H
authors.lastname: Inoue
authors.forename: M
authors.initials: M
authors.lastname: Deguchi
authors.forename: K
authors.initials: K
authors.lastname: Sugimoto
authors.forename: T
authors.initials: T
authors.lastname: Sakai
authors.forename: S
authors.initials: S
authors.lastname: Ohmori
authors.forename: K
authors.initials: K
authors.lastname: Murata
authors.forename: T
authors.initials: T
authors.lastname: Nakano
authors.forename: K
authors.initials: K
authors.lastname: Yamakado
authors.forename: K
authors.initials: K
authors.lastname: Takeda
mesh_terms: D000279:Administration, Cutaneous; D000970:Antineoplastic Agents / Q000009:adverse effects*; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000628:therapy*; D002406:Catheterization, Peripheral / Q000009:adverse effects*; D016461:Chemoembolization, Therapeutic / Q000009:adverse effects*; D003131:Combined Modality Therapy; D000431:Ethanol / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008099:Liver / Q000378:metabolism*; D008111:Liver Function Tests; D008113:Liver Neoplasms / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015911:Sclerotherapy / Q000009:adverse effects*
chemical_list: D000970:Antineoplastic Agents; D000431:Ethanol